for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover PharmAsia News
  [1 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 1875-7774
   Published by Informa plc Homepage  [16 journals]
  • Delays As Korea Grapples With Immuno-Oncology Drug Coverage
    • Abstract: With some of the new immuno-oncology drugs have already been launched in South Korea, experts are emphasizing the need to rapidly reimburse the innovative and pricey cancer therapies to reduce patients’ financial burden, amid debate over the best way of calculating prices.
      PubDate: Wed, 29 Jun 2016 00:50:01 -040
       
  • India Liberalizes Foreign Investments But Will Money Flow'
    • Abstract: Following the easing of India’s foreign direct investment norms in the pharmaceutical sector, reforms are expected to buoy foreign capital inflows and investor sentiment, especially private equity, though some opponents claim it may potentially have a dire impact on India's future medicines security.
      PubDate: Tue, 28 Jun 2016 22:25:02 -040
       
  • China Aiming To Slash Hospital Medical Cost Growth By Half
    • Abstract: Transitionally strong urban hospital market will be cut even deeper, forcing drug makers to actively expand to lower-tiered county hospitals and grassroots clinics for growth.
      PubDate: Tue, 28 Jun 2016 22:15:02 -040
       
  • Turkey Regulatory Update: HPV Vaccine, Device Tracking, Illegal Websites
    • Abstract: An HPV vaccine will be added to Turkey’s national program of immunization, while a new tracking system for devices has started, and a crackdown on illegal drug sale websites is gaining momentum.
      PubDate: Tue, 28 Jun 2016 21:40:01 -040
       
  • New $350m Site To Build Pfizer’s China Biosimilar Capacity
    • Abstract: While some multinationals appear concerned about China's slowing economy and their business prospects in this market, others are forging ahead with major new investments, including Pfizer, which has just unveiled plans for a large biosimilars production and R&D site.
      PubDate: Tue, 28 Jun 2016 02:35:01 -040
       
  • The Brexit Timebomb: Expect Effects On Regulation, IP, R&D And
           Trade
    • Abstract: June 24 was a seismic day, in more ways than one. The UK's decision to withdraw from the EU may have elated more than half of the voting public, but it has caused deep disappointment, anxiety and anger among many millions more in the UK, Europe and around the world.
      PubDate: Mon, 27 Jun 2016 22:45:02 -040
       
  • Brexit Good For UK Firms And Emerging Markets'
    • Abstract: Despite creating shockwaves around the globe, the UK’s ‘Brexit’ vote to leave the EU is expected by analysts to positively impact European pharma companies such as GSK, Sanofi and AstraZeneca. But the impact on product sales and emerging markets will be more of a mixed bag.
      PubDate: Mon, 27 Jun 2016 22:20:01 -040
       
  • INTERVIEW: Korea Initiative Aims To Create Global Clinical Trial Hub
    • Abstract: In a recent interview with PharmAsia News, the head of the Korea Clinical Trial Global Initiative stressed the importance of continued government support in boosting the country’s competitiveness in clinical trials, amid narrowing gaps with its Asian rivals. He also talked about why the initiative is focusing on attracting early phase work from foreign firms and what South Korea needs to do to maintain its edge.
      PubDate: Mon, 27 Jun 2016 02:10:02 -040
       
  • Takeda Returns Selected Assets Under Bumpy Amgen Alliance
    • Abstract: Takeda is unwinding another part of its broad 2008 alliance with Amgen for the Japanese development of a portfolio of molecules, returning rights to selected assets - including trebananib - as it continues to hone its strategic focus.
      PubDate: Mon, 27 Jun 2016 00:50:00 -040
       
  • Brexit – Indian Pharma’s Diversified Play A Buffer'
    • Abstract: Indian markets slumped on June 24 after the UK voted to exit the EU, though industry experts had mixed views on how things may pan out for Indian drug firms with an exposure in Britain or Europe as a whole. Most concurred only that there would be turbulence in the currency markets in the short term.
      PubDate: Sun, 26 Jun 2016 20:50:01 -040
       
  • Turkey Price Pressure Hits Profits And Market Growth
    • Abstract: While the country’s pharma market grew well last year, Turkey’s relentless pressure on drug prices has been taking its toll on the industry’s profitability, shows a new report from the local manufacturers’ association. Over the past few years, the market has actually been shrinking when adjusted for inflation.
      PubDate: Fri, 24 Jun 2016 04:00:01 -040
       
  • Regulator Reforms Coming Soon In Thailand'
    • Abstract: Proposals for the reform of Thailand’s regulatory body are coming up soon for political discussion, and if adopted aim to drive growth in the biopharma and biotech sectors amid tough regional competition for investment from other Asian countries.
      PubDate: Thu, 23 Jun 2016 22:35:00 -040
       
  • Sun Joins Indian Firms Ramping Up In OTCs To Spread Risk
    • Abstract: Sun Pharma, the world’s fifth-largest generics maker, has become the latest in a string of Indian drug companies to ramp up its interest in the OTC sector as it seeks to buffer its revenue stream from regulatory uncertainties and currency volatility.
      PubDate: Thu, 23 Jun 2016 22:00:01 -040
       
  • Korean Tagrisso Launch Builds On Extensive Local Data
    • Abstract: AstraZeneca's Tagrisso has debuted in South Korea, raising hopes and treatment options for certain types of lung cancer patients, but the product will face immediate local direct competition from Hanmi’s recently launched rival olmutinib.
      PubDate: Thu, 23 Jun 2016 01:55:01 -040
       
  • Another Setback As Delays, Costs Spiral For AnGes’ Lead Product
    • Abstract: AnGes MG has changed the global development tack for its troubled lead gene-based therapy, terminating a large international Phase III study in a refocusing that it hopes will save time and money.
      PubDate: Thu, 23 Jun 2016 01:20:01 -040
       
  • Sanofi Dives Deep Into Communities As China Elevates GPs’ Role
    • Abstract: After bagging initial success in China's county hospital market, Sanofi is now targeting another potentially huge sector to drive growth: urban health service centers. While a policy tailwind to emphasize GPs’ role will help, segmented health insurance coverage, poor care quality, and lack of education will make the company's ambitious goal challenging.
      PubDate: Wed, 22 Jun 2016 22:05:02 -040
       
  • China Regulatory Changes Benefit Lee/RegeneRx Ophthalmic Alliance
    • Abstract: China’s allowance of early clinical trials for drugs sourced outside of the country will help domestic companies develop innovative drugs for the domestic market, as shown by the licensing deal between Lee’s Pharma and RegeneRx for a dry eye syndrome treatment. With the China xerophthalmia segment showing rapid growth, the country may eventually become one of the biggest markets in the world for RGN-259.
      PubDate: Wed, 22 Jun 2016 03:00:01 -040
       
  • Singapore Moves Upstream In The Medtech Value Chain
    • Abstract: Singapore set out to build a knowledge-based economy some 25 years ago and biomedical sciences have been a key focus of successive five-year R&D funding initiatives. The country has a lot to show after a quarter century of investment.
      PubDate: Tue, 21 Jun 2016 21:00:01 -040
       
  • MSD Accesses Korea Oncology Innovation Through State Fund
    • Abstract: In an ongoing series of joint R&D programs with big foreign pharma firms, the Korea Drug Development Fund has tied up with MSD to support the development of novel cancer therapies.
      PubDate: Tue, 21 Jun 2016 03:40:01 -040
       
  • Takeda Cements Norovirus Lead Through Vaccine Trial Start
    • Abstract: Takeda has initiated dosing in the first field trial globally with a candidate vaccine for norovirus, maintaining its clear development lead in the area.
      PubDate: Tue, 21 Jun 2016 01:15:00 -040
       
  • Indian E-Chemists Decry Regulatory ‘Witch Hunt’ Amid Offline
           Rival Opposition
    • Abstract: India's e-pharmacy start-ups say they're being harassed by regulators and have called on Prime Minister Narendra Modi's government to stop the "witch-hunt" that they allege is being instigated by their bricks-and-mortar rivals who form a powerful lobby in the country.
      PubDate: Mon, 20 Jun 2016 20:35:01 -040
       
  • Big US Step For Mitsubishi Tanabe As Edaravone Filed For ALS
    • Abstract: Japan's Mitsubishi Tanabe has taken an important step forward in the US with an approval filing for what will be its key strategic product in this market.
      PubDate: Mon, 20 Jun 2016 02:55:01 -040
       
  • What Slowdown' Chinese Maker Splashing Big On Promotion To Bolster
           Prices, Growth
    • Abstract: Could the economic slowdown in China actually translate into opportunities for domestic drug makers? A recent filing for an initial public offering reveals at least one company is forging full speed ahead by spending big on promotion and planning to add over a thousand sales reps, as it looks to shore up product prices and move deeper into the county-level sector.
      PubDate: Sun, 19 Jun 2016 22:15:01 -040
       
  • INTERVIEW: Bayer’s Zieler On Building An Asian Alliance Trove
    • Abstract: Bayer AG is experimenting with both traditional and new collaboration models as part of its innovation strategy and the German multinational appears keen to build on early gains in scientific hotspots in Asia. Claus Zieler, senior vice-president and head of commercial operations, Bayer pharmaceuticals division Asia-Pacific, explains how the company is faring in the region.
      PubDate: Sun, 19 Jun 2016 21:35:00 -040
       
  • China Plan To Exempt More Devices From Trials To Save Time, Costs
    • Abstract: China's Food and Drug Administration is inviting feedback on a new batch of medical devices that it intends to exempt from having to undergo local clinical trials. The agency's proposal, if adopted, would make it much easier and less costly for companies that want to place these devices on the Chinese market.
      PubDate: Fri, 17 Jun 2016 03:35:00 -040
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 23.20.252.75
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2015